Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized Study Evaluating the Efficacy and Safety of Continued and Re-induced Bevacizumab in Combination With Chemotherapy for Patients With Locally Recurrent or Metastatic Breast Cancer After First-line Chemotherapy and Bevacizumab Treatment

NCT01250379 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01250379
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01250379 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized Study Evaluating the Efficacy and Safety of Continued and Re-induced Bevacizumab in Combination With Chemotherapy for Patients With Locally Recurrent or Metastatic Breast Cancer After First-line Chemotherapy and Bevacizumab Treatment
Lead sponsor
Hoffmann-La Roche
Phase
Phase 3
Overall status
Completed
Start date
February 28, 2011
Completion date
March 31, 2015
Enrollment
494 (actual)
Sites
132

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer